Eli Lilly and Company (NYSE:LLY) Updates FY 2026 Earnings Guidance

Eli Lilly and Company (NYSE:LLY) updated its FY 2026 earnings guidance on Wednesday morning. The company provided EPS guidance of 35.500-36.500 for the period, compared to the consensus earnings per share estimate of 36.120. The company issued revenue guidance of $85.0 billion-$87.0 billion, compared to the consensus revenue estimate of $85.4 billion.

Eli Lilly and Company Price Performance

Shares of NYSE LLY traded down $10.95 during trading hours on Friday, reaching $1,180.99. 1,311,849 shares of the stock traded hands, compared to its average volume of 3,132,935. The company’s 50-day simple moving average is $1,157.76 and its two-hundred day simple moving average is $1,046.57. The company has a market capitalization of $1.11 trillion, a P/E ratio of 39.60, a price-to-earnings-growth ratio of 1.41 and a beta of 0.51. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,249.45. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, beating analysts’ consensus estimates of $6.40 by $1.98. The business had revenue of $22.97 billion for the quarter, compared to analysts’ expectations of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 103.84%. The business’s quarterly revenue was up 47.7% on a year-over-year basis. During the same period last year, the business earned $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Equities research analysts forecast that Eli Lilly and Company will post 36 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s payout ratio is currently 23.22%.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on LLY shares. UBS Group set a $1,376.00 price objective on Eli Lilly and Company in a research note on Friday. Leerink Partners increased their target price on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the company an “outperform” rating in a report on Thursday, June 25th. Wolfe Research reiterated an “outperform” rating and issued a $1,350.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, May 21st. Barclays increased their price objective on Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the company an “overweight” rating in a research note on Monday, May 4th. Finally, Weiss Ratings raised shares of Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, July 1st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus price target of $1,292.18.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Strong Q2 beat and raised outlook: Lilly reported $22.97 billion in quarterly revenue, up 47.7% year over year, and EPS of $8.38 versus the $6.40 consensus. Management raised 2026 revenue guidance to approximately $85 billion-$87 billion, supported by surging demand for Mounjaro and Zepbound. Eli Lilly Stock Jumps Over 5% as Mounjaro Sales Surge 91%
• Positive Sentiment: Incretin momentum remains the central growth driver: Mounjaro sales increased 91%, while Mounjaro and Zepbound together generated nearly $15 billion and roughly two-thirds of quarterly sales. Foundayo adoption is accelerating, Medicare access is expanding, and retatrutide is progressing toward a potential 2027 filing. LLY Q2 Earnings Call Raises Outlook as Foundayo Gains Traction
• Positive Sentiment: Analysts remain bullish: Truist raised its price target from $1,370 to $1,376 and maintained a Buy rating, citing Lilly’s incretin performance and long-term growth prospects. Cantor Fitzgerald also raised its target to $1,410 and kept an Overweight rating. Truist price target update
• Neutral Sentiment: Competitive position has improved: Lilly and Novo Nordisk both beat quarterly estimates and raised guidance, but investor confidence has increasingly favored Lilly as its obesity-drug sales momentum outpaces Novo’s. The divide between Eli Lilly and Novo Nordisk is widening
• Positive Sentiment: Legal overhang eased: A U.S. court dismissed an antitrust lawsuit targeting the GLP-1 drug market, a favorable development for Lilly and Novo Nordisk. Lilly, Novo defeat antitrust lawsuit over GLP-1 drug market
• Negative Sentiment: Expectations and execution risks are rising: Lilly trades at a high earnings multiple after its sharp advance. Analysts note that manufacturing capacity, supply availability, pricing, and broader access could constrain demand, while expanded distribution through Amazon and Medicare may intensify competition and pressure economics. Eli Lilly: Fine Q2 2026 Results, But Alertness Required

Institutional Investors Weigh In On Eli Lilly and Company

A number of institutional investors have recently modified their holdings of LLY. Brighton Jones LLC raised its holdings in shares of Eli Lilly and Company by 22.0% during the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after acquiring an additional 1,730 shares in the last quarter. Schnieders Capital Management LLC. increased its position in Eli Lilly and Company by 16.7% in the second quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock worth $6,231,000 after purchasing an additional 1,141 shares during the last quarter. Pinnacle Financial Partners Inc. raised its stake in Eli Lilly and Company by 4.7% during the third quarter. Pinnacle Financial Partners Inc. now owns 42,638 shares of the company’s stock valued at $32,533,000 after purchasing an additional 1,902 shares in the last quarter. Revolve Wealth Partners LLC lifted its position in Eli Lilly and Company by 2.8% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after purchasing an additional 40 shares during the last quarter. Finally, Graney & King LLC grew its stake in shares of Eli Lilly and Company by 11.0% in the 4th quarter. Graney & King LLC now owns 202 shares of the company’s stock worth $217,000 after buying an additional 20 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.